Nishimura Shiori, Kumamaru Hiraku, Shoji Satoshi, Nakatani Eiji, Yamamoto Hiroyuki, Ichihara Nao, Sandhu Alexander T, Miyachi Yoshiki, Miyata Hiroaki, Kohsaka Shun
Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Shizuoka Graduate University of Public Health, Shizuoka, Japan.
Res Pract Thromb Haemost. 2023 Mar 25;7(3):100129. doi: 10.1016/j.rpth.2023.100129. eCollection 2023 Mar.
In older patients with atrial fibrillation (AF), frailty is frequently prevalent. However, the prognostic value of frailty for adverse events after initiation of oral anticoagulants (OACs) is unclear.
We assessed whether frailty at the time of OAC initiation is associated with subsequent bleeding or embolic events.
We extracted patients aged ≥65 years with nonvalvular AF in whom OACs were initiated from a universal administrative claims database incorporating primary and hospital care records in Shizuoka, Japan, between 2012 and 2018. Frailty was assessed using the electronic frailty index (eFI). The association of frailty with bleeding events and ischemic stroke/transient ischemic attack were evaluated using the Fine-Gray model and restricted cubic spline model.
Among 12,585 patients with AF, 7.8% were categorized as fit, 31.5% as mildly frail, 34.8% as moderately frail, and 25.9% as severely frail. The risk of bleeding was associated with a higher eFI (adjusted subdistribution hazard ratio [95% CI] for fit or mild frailty: 1.15 [1.02-1.30]; moderate frailty: 1.42 [1.24-1.61]; and severe frailty: 1.86 [1.61-2.15]), whereas the association was weaker for ischemic stroke/transient ischemic attack. The spline models demonstrated that the relative hazard for bleeding increased steeply with increasing eFI.
Patients with frailty in whom OAC therapy is initiated have higher risk of bleeding, highlighting the importance of discussing this increased risk with patients with AF who have frailty and assessing frailty at the time of OAC initiation.
在老年房颤(AF)患者中,衰弱现象经常普遍存在。然而,衰弱对于口服抗凝剂(OACs)起始治疗后不良事件的预后价值尚不清楚。
我们评估了OAC起始治疗时的衰弱是否与随后的出血或栓塞事件相关。
我们从一个包含日本静冈县初级和医院护理记录的通用行政索赔数据库中提取了2012年至2018年间起始使用OACs的年龄≥65岁的非瓣膜性AF患者。使用电子衰弱指数(eFI)评估衰弱情况。使用Fine-Gray模型和受限立方样条模型评估衰弱与出血事件以及缺血性卒中/短暂性脑缺血发作的相关性。
在12585例AF患者中,7.8%被分类为健康,31.5%为轻度衰弱,34.8%为中度衰弱,25.9%为重度衰弱。出血风险与较高的eFI相关(健康或轻度衰弱的校正亚分布风险比[95%CI]:1.15[1.02-1.30];中度衰弱:1.42[1.24-1.61];重度衰弱:1.86[1.61-2.15]),而对于缺血性卒中/短暂性脑缺血发作,这种相关性较弱。样条模型表明,出血的相对风险随着eFI的增加而急剧上升。
起始OAC治疗的衰弱患者出血风险更高,这凸显了与衰弱的AF患者讨论这种增加的风险以及在OAC起始治疗时评估衰弱情况的重要性。